Systemic Treatment of Body‐Wide Duchenne Muscular Dystrophy Symptoms
Clinical Pharmacology & Therapeutics · 2024-12 · 116 (6) · 1472-1484
DOI: 10.1002/cpt.3363 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 04.07.2024. Verfasst von Patryk Konieczny. Beteiligte Einrichtung: Institute of Human Biology and Evolution, Faculty of Biology, Adam Mickiewicz University, Poznań, Poland. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, Dystrophin, Muscle, Skeletal. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Polish National Science Centre.
Abstract (Originalsprache)
Duchenne muscular dystrophy (DMD) is a fatal X‐linked disease that leads to premature death due to the loss of dystrophin. Current strategies predominantly focus on the therapeutic treatment of affected skeletal muscle tissue. However, certain results point to the fact that with successful treatment of skeletal muscle, DMD‐exposed latent phenotypes in tissues, such as cardiac and smooth muscle, might lead to adverse effects and even death. Likewise, it is now clear that the absence of dystrophin affects the function of the nervous system, and that this phenotype is more pronounced when shorter dystrophins are absent, in addition to the full‐length dystrophin that is present predominantly in the muscle. Here, I focus on the systemic aspects of DMD, highlighting the ubiquitous expression of the dystrophin gene in human tissues. Furthermore, I describe therapeutic strategies that have been tested in the clinic and point to unresolved questions regarding the function of distinct dystrophin isoforms, and the possibility of current therapeutic strategies to tackle phenotypes that relate to their absence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Human Biology and Evolution, Faculty of Biology, Adam Mickiewicz University, Poznań, Poland.
ORCID-Profile: Patryk Konieczny
Förderung
- Polish National Science Centre
Zitieren
APA
Konieczny, P. (2024). Systemic Treatment of Body‐Wide Duchenne Muscular Dystrophy Symptoms. Clinical Pharmacology & Therapeutics, 116(6), 1472-1484. https://doi.org/10.1002/cpt.3363
Vancouver
Konieczny P. Systemic Treatment of Body‐Wide Duchenne Muscular Dystrophy Symptoms. Clinical Pharmacology & Therapeutics. 2024;116(6):1472-1484. doi:10.1002/cpt.3363
BibTeX
@article{Konieczny2024,
author = {Konieczny, Patryk},
title = {Systemic Treatment of Body‐Wide Duchenne Muscular Dystrophy Symptoms},
journal = {Clinical Pharmacology & Therapeutics},
year = {2024},
volume = {116},
number = {6},
pages = {1472--1484},
doi = {10.1002/cpt.3363}
}
EUVIMED